Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA20022A3" target="_blank" >RIV/61988987:17110/19:A20022A3 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/19:00111949 RIV/00216208:11120/19:43918748 RIV/00216208:11150/19:10397366 RIV/61989592:15110/19:73595631 and 5 more

Result on the web

<a href="https://www.jcancer.org/v10p5041.pdf" target="_blank" >https://www.jcancer.org/v10p5041.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.7150/jca.29308" target="_blank" >10.7150/jca.29308</a>

Result language

angličtina

Original language name

Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia

Original language description

Introduction: Clinical trials have demonstrated the effectiveness of the CD30-targeted antibody- drug conjugate brentuximab vedotin (BV) for the treatment of relapsed/refractory Hodgkin lymphoma (R/R HL). In this study, we report on outcomes with BV in a real-world setting using data collected in clinics in the Czech Republic and Slovakia. Patients and Methods: Clinical and epidemiological data for patients with R/R HL who received treatment with BV at eight centers across the Czech Republic and Slovakia were examined. Data were amalgamated and analyzed retrospectively. Results: Clinical data for 58 patients (median age: 30.5 years) with R/R HL who received BV during the course of their treatment were collected and analyzed. Patients had received a median of 3 prior treatment regimens and most (91%) were treated with BV after relapse following autologous stem cell transplantation. Therapeutic responses after BV included 19 (33%) complete responses (CRs) and 8 (14%) partial responses. CRs occurred more frequently in patients who had received fewer prior treatment regimens. The 1-, 2-, and 3-year overall survival (OS) rates from initiation of BV were 78%, 62%, and 41%, respectively. Conclusion: Response rates and OS in this analysis of BV in real-world settings in the Czech Republic and Slovakia were consistent with those reported for pivotal clinical trials and from previous studies outside the clinical trial setting. The results support the efficacy of BV for treatment of R/R HL in real-life clinical practice.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

JOURNAL OF CANCER

ISSN

1837-9664

e-ISSN

—

Volume of the periodical

10

Issue of the periodical within the volume

21

Country of publishing house

AU - AUSTRALIA

Number of pages

7

Pages from-to

5041-5048

UT code for WoS article

000484111400004

EID of the result in the Scopus database

—